Argenica Therapeutics Ltd (AGN) - Total Assets
Based on the latest financial reports, Argenica Therapeutics Ltd (AGN) holds total assets worth AU$5.20 Million AUD (≈ $3.68 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See AGN book value for net asset value and shareholders' equity analysis.
Argenica Therapeutics Ltd - Total Assets Trend (2019–2024)
This chart illustrates how Argenica Therapeutics Ltd's total assets have evolved over time, based on quarterly financial data.
Argenica Therapeutics Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Argenica Therapeutics Ltd's total assets of AU$5.20 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 95.6% |
| Accounts Receivable | AU$421.45K | 3.8% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$1.00K | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Argenica Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Argenica Therapeutics Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Argenica Therapeutics Ltd's current assets represent 100.0% of total assets in 2024, an increase from 99.7% in 2019.
- Cash Position: Cash and equivalents constituted 95.6% of total assets in 2024, up from 90.6% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 3.8% of total assets.
Argenica Therapeutics Ltd Competitors by Total Assets
Key competitors of Argenica Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $1.30 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥38.02 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.48 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Argenica Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.96 | 6.95 | 21.87 |
| Quick Ratio | 2.96 | 6.95 | 21.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$3.44 Million | AU$13.19 Million | AU$1.22 Million |
Argenica Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Argenica Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.70 |
| Latest Market Cap to Assets Ratio | 1.40 |
| Asset Growth Rate (YoY) | -32.6% |
| Total Assets | AU$11.04 Million |
| Market Capitalization | $15.45 Million USD |
Valuation Analysis
Above Book Valuation: The market values Argenica Therapeutics Ltd's assets above their book value (1.40x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Argenica Therapeutics Ltd's assets decreased by 32.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Argenica Therapeutics Ltd (2019–2024)
The table below shows the annual total assets of Argenica Therapeutics Ltd from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | AU$11.04 Million ≈ $7.81 Million |
-32.60% |
| 2023-12-31 | AU$16.38 Million ≈ $11.59 Million |
+71.66% |
| 2022-12-31 | AU$9.54 Million ≈ $6.75 Million |
+5.50% |
| 2021-12-31 | AU$9.04 Million ≈ $6.40 Million |
+24.35% |
| 2020-12-31 | AU$7.27 Million ≈ $5.15 Million |
+1825.67% |
| 2019-12-31 | AU$377.66K ≈ $267.22K |
-- |
About Argenica Therapeutics Ltd
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Aus… Read more